CANCER:

Skin Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Merkel Cell Carcinoma (20)

Squamous Cell Skin Cancer (20)

Basal Cell Carcinoma (17)

Merkel Cell Carcinoma (20)

Squamous Cell Skin Cancer (20)

Basal Cell Carcinoma (17)

›

No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 2 weeks (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 2wk	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 2 weeks pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 2 weeks - (New A1)
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week (New A1) nivolumab / relatlimab Sensitive : A1 Bristol-Myers Squibb Press Release - 1wk	nivolumab/relatlimab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week nivolumab / relatlimab Sensitive : A1 Bristol-Myers Squibb Press Release - 1 week - (New A1)
BRAF V600	Melanoma	BRAF V600	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3wk	encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) vemurafenib + cobimetinib Sensitive : A1 ESMO 2022 - 3wk	vemurafenib + cobimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks vemurafenib + cobimetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	pembrolizumab Sensitive: A1 - Approval J Am Acad Dermatol - 3 weeks (New C3) pembrolizumab Sensitive : A1 J Am Acad Dermatol - 3wk	pembrolizumab Sensitive: A1 - Approval J Am Acad Dermatol - 3 weeks pembrolizumab Sensitive : A1 J Am Acad Dermatol - 3 weeks - (New C3)
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	pembrolizumab Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) pembrolizumab Sensitive : B ESMO 2022 - 3wk	pembrolizumab Sensitive: B - Late Trials ESMO 2022 - 3 weeks pembrolizumab Sensitive : B ESMO 2022 - 3 weeks - (New B)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria Cancer Treat Rev - 3 weeks (New C3) encorafenib + binimetinib Sensitive : C2 Cancer Treat Rev - 3wk	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria Cancer Treat Rev - 3 weeks encorafenib + binimetinib Sensitive : C2 Cancer Treat Rev - 3 weeks - (New C3)
PAK4 overexpression	Melanoma	PAK4 overexpression	Melanoma	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
PMS2 mutation	Melanoma	PMS2 mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KIT mutation	Melanoma	KIT mutation	Melanoma	imatinib + toripalimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) imatinib + toripalimab Sensitive : C3 ESMO 2022 - 3wk	imatinib + toripalimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks imatinib + toripalimab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	vorinostat Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) vorinostat Sensitive : C3 ESMO 2022 - 3wk	vorinostat Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks vorinostat Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ipilimumab + tebentafusp Sensitive : C3 ESMO 2022 - 3wk	ipilimumab + tebentafusp Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ipilimumab + tebentafusp Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) dalpiciclib Sensitive : C3 ESMO 2022 - 3wk	dalpiciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks dalpiciclib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1	fluorouracil topical Sensitive: A1 - Approval fluorouracil topical Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	trametinib Resistant: A1 - Approval trametinib Resistant : A1	trametinib Resistant: A1 - Approval trametinib Resistant : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1	vemurafenib Sensitive: A1 - Approval vemurafenib Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1	sonidegib Sensitive: A1 - Approval sonidegib Sensitive : A1
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1	ipilimumab Sensitive: A1 - Approval ipilimumab Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1	encorafenib + binimetinib Sensitive: A1 - Approval encorafenib + binimetinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1	vemurafenib + cobimetinib Sensitive: A1 - Approval vemurafenib + cobimetinib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1	cemiplimab Sensitive: A1 - Approval cemiplimab Sensitive : A1
LDH elevation	Melanoma	LDH elevation	Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1

Skin Cancer

Associations(1049)

Associations
(1049)